CA2496918A1 - Procedes chromatographiques de purification d'adenovirus - Google Patents

Procedes chromatographiques de purification d'adenovirus Download PDF

Info

Publication number
CA2496918A1
CA2496918A1 CA002496918A CA2496918A CA2496918A1 CA 2496918 A1 CA2496918 A1 CA 2496918A1 CA 002496918 A CA002496918 A CA 002496918A CA 2496918 A CA2496918 A CA 2496918A CA 2496918 A1 CA2496918 A1 CA 2496918A1
Authority
CA
Canada
Prior art keywords
medium
adenovirus
media
cells
chromatographic medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002496918A
Other languages
English (en)
Inventor
Joseph Senesac
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Introgen Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2496918A1 publication Critical patent/CA2496918A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des procédés permettant de faire passer des préparations de particules d'adénovirus à travers un milieu chromatographique afin de fournir des particules d'adénovirus purifiées.
CA002496918A 2002-08-28 2003-08-27 Procedes chromatographiques de purification d'adenovirus Abandoned CA2496918A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40659102P 2002-08-28 2002-08-28
US60/406,591 2002-08-28
PCT/US2003/026831 WO2004020971A2 (fr) 2002-08-28 2003-08-27 Procedes chromatographiques de purification d'adenovirus

Publications (1)

Publication Number Publication Date
CA2496918A1 true CA2496918A1 (fr) 2004-03-11

Family

ID=31978321

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002496918A Abandoned CA2496918A1 (fr) 2002-08-28 2003-08-27 Procedes chromatographiques de purification d'adenovirus

Country Status (5)

Country Link
US (1) US20040106184A1 (fr)
EP (1) EP1585964A4 (fr)
AU (1) AU2003268210A1 (fr)
CA (1) CA2496918A1 (fr)
WO (1) WO2004020971A2 (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0968284B1 (fr) * 1996-11-20 2006-12-13 Introgen Therapeutics, Inc. Procede ameliore pour production et purification de vecteurs d'adenovirus
US20040229335A1 (en) * 2003-05-15 2004-11-18 Introgen Therapeutics, Inc. Methods and compositions for the production of adenoviral vectors
DK2368975T3 (en) 2004-12-23 2015-01-05 Medimmune Llc Non-tumorigenic MDCK cell line for the propagation of viruses
CA2600922C (fr) * 2005-03-04 2013-06-04 Northwestern University Separation de nanotubes de carbone dans des gradients de densite
ES2533970T3 (es) * 2005-03-08 2015-04-16 Aptose Biosciences Inc. Uso de interleucina 17E para el tratamiento de cáncer
EP1736538A1 (fr) 2005-06-21 2006-12-27 Cytos Biotechnology AG Procédé pour la purification préparative de particules pseudo-virales (VLPs)
WO2007059473A2 (fr) * 2005-11-12 2007-05-24 Introgen Therapeutics, Inc. Procedes de production et de purification de vecteurs adenoviraux
KR101425690B1 (ko) * 2006-08-30 2014-08-06 노쓰웨스턴유니버시티 단분산 단일벽 탄소 나노튜브 군집 및 그를 제공하는 관련된 방법
EP2615167A1 (fr) 2006-09-15 2013-07-17 MedImmune, LLC Méthode d'élimination de contaminants d'ADN des préparations de virus
ES2559421T3 (es) * 2007-03-14 2016-02-12 Takeda Vaccines, Inc. Purificación de partículas similares a virus
US8936934B2 (en) * 2008-04-01 2015-01-20 University Of North Carolina At Charlotte Bioreactor assembly and associated methods
US8202726B2 (en) * 2008-09-24 2012-06-19 Medimmune, Llc Methods for cultivating cells, propagating and purifying viruses
KR102150027B1 (ko) * 2009-03-02 2020-10-26 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 종양 선택적 ｅ１ａ 및 ｅ１ｂ 돌연변이
RU2560976C2 (ru) 2009-05-12 2015-08-20 Трансген Са Способ продуцирования и очистки ортопоксвируса
AP3390A (en) 2010-09-20 2015-08-31 Crucell Holland Bv Therapeutic vaccination against active tuberculosis
CA2809463C (fr) 2010-09-27 2021-05-25 Crucell Holland B.V. Regime de vaccination de type amorce rappel heterologue contre la malaria
WO2012134987A1 (fr) 2011-03-25 2012-10-04 Genentech, Inc. Nouveaux procédés de purification de protéines
SG10201603931TA (en) * 2011-06-08 2016-07-28 Agency Science Tech & Res Purification Of Biological Products By Constrained Cohydration Chromatography
US20130122038A1 (en) 2011-11-14 2013-05-16 The United States Of America As Represented By The Secretary Of The Department Heterologous prime-boost immunization using measles virus-based vaccines
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
WO2013135615A1 (fr) 2012-03-12 2013-09-19 Crucell Holland B.V. Lots d'adénovirus recombinants ayant des extrémités terminales modifiées
CA2867955C (fr) 2012-03-22 2023-02-07 Crucell Holland B.V. Vaccin contre le vrs
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
WO2014141304A1 (fr) * 2013-03-12 2014-09-18 Indian Council Of Medical Research Procédé de production de cyclosporine-a (cyc-a) au moyen du champignon tolypocladium sp., souche nrrl n° 18950
AP2015008815A0 (en) 2013-04-25 2015-10-31 Crucell Holland Bv Stabilized soluble prefusion rsv f polypeptides
PE20160045A1 (es) 2013-06-17 2016-02-18 Crucell Holland Bv Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados
EP3054006A1 (fr) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Purification de particule de virus adéno-associé recombinant avec une chromatographie à échange d'anions en plusieurs étapes
EP3054007A1 (fr) * 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Purification de particules de virus adéno-associés de recombinaison comprenant une étape de purification par affinité immunologique
EP3283634B1 (fr) 2015-04-14 2019-05-22 Janssen Vaccines & Prevention B.V. Adénovirus recombinant exprimant deux transgènes comprenant un promoteur bidirectionnel
CN116059336A (zh) 2015-07-07 2023-05-05 扬森疫苗与预防公司 针对rsv的疫苗
WO2017005848A1 (fr) 2015-07-07 2017-01-12 Janssen Vaccines & Prevention B.V. Polypeptides f du vrs de pré-fusion solubles stabilisés
US9663766B2 (en) * 2015-07-24 2017-05-30 Bio-Rad Laboratories, Inc. Methods for purifying adenovirus vectors
SI3439672T1 (sl) 2016-04-05 2021-02-26 Janssen Vaccines & Prevention B.V. Stabiliziran topen pre-fuzijski F protein RSV za uporabo v profilaksi okužbe z RSV
KR102401247B1 (ko) 2016-04-05 2022-05-25 얀센 백신스 앤드 프리벤션 비.브이. Rsv에 대한 백신
RU2758238C2 (ru) 2016-05-12 2021-10-26 Янссен Вэксинс Энд Превеншн Б.В. Эффективный и сбалансированный двунаправленный промотор
MX2018014699A (es) 2016-05-30 2019-02-28 Janssen Vaccines & Prevention Bv Proteinas f de prefusion del vrs estabilizadas.
EP3472327B1 (fr) 2016-06-20 2020-08-19 Janssen Vaccines & Prevention B.V. Promoteur bidirectionnel puissant et équilibré
GB201612248D0 (en) * 2016-07-14 2016-08-31 Puridify Ltd New process
JP7229151B2 (ja) 2016-07-14 2023-02-27 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｈｐｖワクチン
EP3500297A1 (fr) 2016-08-16 2019-06-26 Regeneron Pharmaceuticals, Inc. Procédés de quantification d'anticorps individuels à partir d'un mélange.
PL3532838T3 (pl) 2016-10-25 2022-10-03 Regeneron Pharmaceuticals, Inc. Metody i systemy analizy danych chromatograficznych
KR102111244B1 (ko) 2017-02-09 2020-05-15 얀센 백신스 앤드 프리벤션 비.브이. 이종 유전자의 발현을 위한 강력한 짧은 프로모터
AU2018267971A1 (en) 2017-05-17 2019-11-07 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
EA202090738A1 (ru) 2017-09-15 2020-06-10 Янссен Вэксинс Энд Превеншн Б.В. Способ безопасного индуцирования иммунитета против rsv
US11603527B2 (en) * 2017-12-27 2023-03-14 Global Life Sciences Solutions Usa Llc Method and kit for viral vector isolation
CN108593823B (zh) * 2018-04-04 2020-10-09 桂林理工大学 一种分离富集大体积水样中三嗪类农药的方法
TW202005694A (zh) 2018-07-02 2020-02-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
KR20220008300A (ko) * 2019-05-14 2022-01-20 얀센 바이오테크 인코포레이티드 정용여과 공정을 사용한 효율적인 불순물 제거
CN114173827A (zh) * 2019-06-28 2022-03-11 武田药品工业株式会社 腺相关病毒纯化方法
CN110714029A (zh) * 2019-11-06 2020-01-21 无锡生基医药科技有限公司 一种慢病毒载体全封闭生产的方法及系统
CL2020002629A1 (es) 2020-10-12 2021-01-15 Taag Genetics S A Nuevo dispositivo de biología molecular para extracción y purificación de ácidos nucleicos desde diferentes tipos de muestras biológicas que comprende resinas de adsorción
CN113416235B (zh) * 2021-06-24 2023-04-25 苏州赛分科技股份有限公司 用于纯化分离病毒类抗原的液相色谱法
CN114317464B (zh) * 2021-12-27 2023-07-04 武汉汇研生物科技股份有限公司 腺相关病毒rAAV9的分离纯化方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4352883A (en) * 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
EP0571014B1 (fr) * 1992-05-18 2004-03-31 Genencor International, Inc. Bactéries produisant des protéases alcalines et production de ces protéases alcalines
US5837520A (en) * 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
US5744304A (en) * 1995-05-30 1998-04-28 Board Of Regents, The University Of Texas System Inflammation-induced expression of a recombinant gene
US6143548A (en) * 1995-08-30 2000-11-07 Genzyme Corporation Chromatographic purification of adeno-associated virus (AAV)
SK70598A3 (en) * 1995-11-30 1999-04-13 Univ Texas Methods and compositions for the diagnosis and treatment of cancer
WO1998000524A1 (fr) * 1996-07-01 1998-01-08 Rhone-Poulenc Rorer S.A. Procede de production d'adenovirus recombinants
US7732129B1 (en) * 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
EP0968284B1 (fr) * 1996-11-20 2006-12-13 Introgen Therapeutics, Inc. Procede ameliore pour production et purification de vecteurs d'adenovirus
US6261823B1 (en) * 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
EP1080218A1 (fr) * 1998-05-27 2001-03-07 University of Florida Procede de preparation de compositions de virus adeno-associes de recombinaison a l'aide d'un gradient d'iodixananol
MXPA01000215A (es) * 1998-06-30 2003-09-10 Lamina Inc Composicion fijadora histologica y metodos de uso.

Also Published As

Publication number Publication date
EP1585964A4 (fr) 2008-07-16
WO2004020971A2 (fr) 2004-03-11
EP1585964A2 (fr) 2005-10-19
WO2004020971A3 (fr) 2007-11-08
US20040106184A1 (en) 2004-06-03
AU2003268210A8 (en) 2004-03-19
AU2003268210A1 (en) 2004-03-19

Similar Documents

Publication Publication Date Title
CA2496918A1 (fr) Procedes chromatographiques de purification d'adenovirus
CA2353787C (fr) Procede ameliore de production et de purification de vecteurs adenoviraux
US7445930B2 (en) Method for the production and purification of adenoviral vectors
US20060166364A1 (en) Use of flexible bag containers for viral production
WO1998022588A9 (fr) Procede ameliore pour production et purification de vecteurs d'adenovirus
US7419808B2 (en) Methods and compositions for the production of adenoviral vectors
WO2007059473A2 (fr) Procedes de production et de purification de vecteurs adenoviraux
WO1999027123A9 (fr) Vecteurs viraux sv40 modifies

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead